Business Model

AVAX’s business model is similar to that of many other biotechnology platform companies. Given that AVAX has a technology platform for producing personalized vaccines for different cancer types with varying levels of engineered anti-genicity, it has the opportunity to continue to develop vaccines in a very efficient and effective manner.

AVAX’s business model and commercialization strategy is to develop new vaccines to late stage clinical development and then strategically partner the continued clinical development and sales, marketing and distribution. Revenue is generated through milestone payments, manufacturing payments and royalties.